Cargando…

Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse

Cannabis abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5‐HT (6) rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Berthoux, Coralie, Hamieh, Al Mahdy, Rogliardo, Angelina, Doucet, Emilie L, Coudert, Camille, Ango, Fabrice, Grychowska, Katarzyna, Chaumont‐Dubel, Séverine, Zajdel, Pawel, Maldonado, Rafael, Bockaert, Joël, Marin, Philippe, Bécamel, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207164/
https://www.ncbi.nlm.nih.gov/pubmed/32329240
http://dx.doi.org/10.15252/emmm.201910605
_version_ 1783530551776378880
author Berthoux, Coralie
Hamieh, Al Mahdy
Rogliardo, Angelina
Doucet, Emilie L
Coudert, Camille
Ango, Fabrice
Grychowska, Katarzyna
Chaumont‐Dubel, Séverine
Zajdel, Pawel
Maldonado, Rafael
Bockaert, Joël
Marin, Philippe
Bécamel, Carine
author_facet Berthoux, Coralie
Hamieh, Al Mahdy
Rogliardo, Angelina
Doucet, Emilie L
Coudert, Camille
Ango, Fabrice
Grychowska, Katarzyna
Chaumont‐Dubel, Séverine
Zajdel, Pawel
Maldonado, Rafael
Bockaert, Joël
Marin, Philippe
Bécamel, Carine
author_sort Berthoux, Coralie
collection PubMed
description Cannabis abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5‐HT (6) receptor‐operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of ∆9‐tetrahydrocannabinol (THC) to mice during adolescence induces a long‐lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long‐term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a 5‐HT (6) receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of 5‐HT (6) receptor‐operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5‐HT (6) receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent cannabis abusers.
format Online
Article
Text
id pubmed-7207164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72071642020-05-12 Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse Berthoux, Coralie Hamieh, Al Mahdy Rogliardo, Angelina Doucet, Emilie L Coudert, Camille Ango, Fabrice Grychowska, Katarzyna Chaumont‐Dubel, Séverine Zajdel, Pawel Maldonado, Rafael Bockaert, Joël Marin, Philippe Bécamel, Carine EMBO Mol Med Articles Cannabis abuse during adolescence confers an increased risk for developing later in life cognitive deficits reminiscent of those observed in schizophrenia, suggesting common pathological mechanisms that remain poorly characterized. In line with previous findings that revealed a role of 5‐HT (6) receptor‐operated mTOR activation in cognitive deficits of rodent developmental models of schizophrenia, we show that chronic administration of ∆9‐tetrahydrocannabinol (THC) to mice during adolescence induces a long‐lasting activation of mTOR in prefrontal cortex (PFC), alterations of excitatory/inhibitory balance, intrinsic properties of layer V pyramidal neurons, and long‐term depression, as well as cognitive deficits in adulthood. All are prevented by administrating a 5‐HT (6) receptor antagonist or rapamycin, during adolescence. In contrast, they are still present 2 weeks after the same treatments delivered at the adult stage. Collectively, these findings suggest a role of 5‐HT (6) receptor‐operated mTOR signaling in abnormalities of cortical network wiring elicited by THC at a critical period of PFC maturation and highlight the potential of 5‐HT (6) receptor antagonists as early therapy to prevent cognitive symptom onset in adolescent cannabis abusers. John Wiley and Sons Inc. 2020-04-24 2020-05-08 /pmc/articles/PMC7207164/ /pubmed/32329240 http://dx.doi.org/10.15252/emmm.201910605 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Berthoux, Coralie
Hamieh, Al Mahdy
Rogliardo, Angelina
Doucet, Emilie L
Coudert, Camille
Ango, Fabrice
Grychowska, Katarzyna
Chaumont‐Dubel, Séverine
Zajdel, Pawel
Maldonado, Rafael
Bockaert, Joël
Marin, Philippe
Bécamel, Carine
Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title_full Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title_fullStr Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title_full_unstemmed Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title_short Early 5‐HT (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
title_sort early 5‐ht (6) receptor blockade prevents symptom onset in a model of adolescent cannabis abuse
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207164/
https://www.ncbi.nlm.nih.gov/pubmed/32329240
http://dx.doi.org/10.15252/emmm.201910605
work_keys_str_mv AT berthouxcoralie early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT hamiehalmahdy early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT rogliardoangelina early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT doucetemiliel early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT coudertcamille early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT angofabrice early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT grychowskakatarzyna early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT chaumontdubelseverine early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT zajdelpawel early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT maldonadorafael early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT bockaertjoel early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT marinphilippe early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse
AT becamelcarine early5ht6receptorblockadepreventssymptomonsetinamodelofadolescentcannabisabuse